PhRMA Statement on House Passage of Reconciliation Spending Bill

WASHINGTON, D.C. (August 12, 2022) – The Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO Stephen J. Ubl released the following statement after the U.S. House of Representatives passed a reconciliation spending bill, which includes a proposal that would allow the government to set prices for prescription medicines:

“After many months of legislative wrangling, we are left with a partisan, government price setting bill that will lead to fewer cures and treatments and doesn’t do nearly enough to make medicines more affordable for most Americans. It is a highly unbalanced bill based on empty promises. We will continue to advocate for commonsense and bipartisan solutions because the American people deserve better.”

About PhRMA

The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are laser focused on developing innovative medicines that transform lives and create a healthier world. Together, we are fighting for solutions to ensure patients can access and afford medicines that prevent, treat and cure disease. Over the last decade, PhRMA member companies have invested more than $800 billion in the search for new treatments and cures, and they support nearly five million jobs in the United States.

Connect with PhRMA

For information on how innovative medicines save lives, please visit:
www.PhRMA.org
www.VotersforCures.org
www.MAT.org
www.Facebook.com/PhRMA
www.X.com/PhRMA